Literature DB >> 21587213

Safeguarding nonhuman primate iPS cells with suicide genes.

Bonan Zhong1, Korashon L Watts, Jennifer L Gori, Martin E Wohlfahrt, Joerg Enssle, Jennifer E Adair, Hans-Peter Kiem.   

Abstract

The development of technology to generate induced pluripotent stem (iPS) cells constitutes one of the most exciting scientific breakthroughs because of the enormous potential for regenerative medicine. However, the safety of iPS cell-related products is a major concern for clinical translation. Insertional mutagenesis, possible oncogenic transformation of iPS cells or their derivatives, or the contamination of differentiated iPS cells with undifferentiated cells, resulting in the formation of teratomas, have remained considerable obstacles. Here, we demonstrate the utility of suicide genes to safeguard iPS cells and their derivatives. We found suicide genes can control the cell fate of iPS cells in vitro and in vivo without interfering with their pluripotency and self-renewal capacity. This study will be useful to evaluate the safety of iPS cell technology in a clinically highly relevant, large animal model and further benefit the clinical use of human iPS cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21587213      PMCID: PMC3182363          DOI: 10.1038/mt.2011.51

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  53 in total

1.  Efficient generation of nonhuman primate induced pluripotent stem cells.

Authors:  Bonan Zhong; Grant D Trobridge; Xiaobing Zhang; Korashon L Watts; Aravind Ramakrishnan; Martin Wohlfahrt; Jennifer E Adair; Hans-Peter Kiem
Journal:  Stem Cells Dev       Date:  2011-02-01       Impact factor: 3.272

2.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

3.  Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model.

Authors:  T Shirakawa; T A Gardner; S C Ko; N Bander; S Woo; A Gotoh; S Kamidono; L W Chung; C Kao
Journal:  J Urol       Date:  1999-09       Impact factor: 7.450

Review 4.  Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.

Authors:  F Ciceri; C Bonini; C Gallo-Stampino; C Bordignon
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

Review 5.  Introduction to the background, principles, and state of the art in suicide gene therapy.

Authors:  Ion Niculescu-Duvaz; Caroline J Springer
Journal:  Mol Biotechnol       Date:  2005-05       Impact factor: 2.695

6.  Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.

Authors:  E Kievit; E Bershad; E Ng; P Sethna; I Dev; T S Lawrence; A Rehemtulla
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

7.  Improved artificial death switches based on caspases and FADD.

Authors:  L Fan; K W Freeman; T Khan; E Pham; D M Spencer
Journal:  Hum Gene Ther       Date:  1999-09-20       Impact factor: 5.695

8.  WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation.

Authors:  Y Hu; L Ding; D M Spencer; G Núñez
Journal:  J Biol Chem       Date:  1998-12-11       Impact factor: 5.157

9.  Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases.

Authors:  Erica A Moehle; E A Moehle; Jeremy M Rock; J M Rock; Ya-Li Lee; Y L Lee; Yann Jouvenot; Y Jouvenot; Russell C DeKelver; R C Dekelver; Philip D Gregory; P D Gregory; Fyodor D Urnov; F D Urnov; Michael C Holmes; M C Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

10.  Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine.

Authors:  T S Lawrence; A Rehemtulla; E Y Ng; M Wilson; J E Trosko; P L Stetson
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

View more
  33 in total

1.  Purging and isolating pluripotent cells, "sweet" dreams become true?

Authors:  Ignacio Sancho-Martinez; Emmanuel Nivet; Juan Carlos Izpisua Belmonte
Journal:  Cell Res       Date:  2011-10-25       Impact factor: 25.617

2.  Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells.

Authors:  Jennifer L Gori; Jason M Butler; Yan-Yi Chan; Devikha Chandrasekaran; Michael G Poulos; Michael Ginsberg; Daniel J Nolan; Olivier Elemento; Brent L Wood; Jennifer E Adair; Shahin Rafii; Hans-Peter Kiem
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

Review 3.  Preclinical studies for induced pluripotent stem cell-based therapeutics.

Authors:  John Harding; Oleg Mirochnitchenko
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

Review 4.  Assessing the risks of genotoxicity in the therapeutic development of induced pluripotent stem cells.

Authors:  So Gun Hong; Cynthia E Dunbar; Thomas Winkler
Journal:  Mol Ther       Date:  2012-12-04       Impact factor: 11.454

5.  Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium.

Authors:  Lan Zhang; Yaohua Pan; Gangjian Qin; Lijuan Chen; Tapan K Chatterjee; Neal L Weintraub; Yaoliang Tang
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

6.  Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques.

Authors:  Cecilia N Barese; Tania C Felizardo; Stephanie E Sellers; Keyvan Keyvanfar; Antonio Di Stasi; Mark E Metzger; Allen E Krouse; Robert E Donahue; David M Spencer; Cynthia E Dunbar
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

Review 7.  Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.

Authors:  Chuanfeng Wu; Cynthia E Dunbar
Journal:  Front Med       Date:  2011-12-27       Impact factor: 4.592

8.  Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells.

Authors:  Jennifer L Gori; Devikha Chandrasekaran; John P Kowalski; Jennifer E Adair; Brian C Beard; Sunita L D'Souza; Hans-Peter Kiem
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

Review 9.  Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy.

Authors:  Eirini P Papapetrou; Axel Schambach
Journal:  Mol Ther       Date:  2016-02-12       Impact factor: 11.454

10.  An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells.

Authors:  Shigeki Yagyu; Valentina Hoyos; Francesca Del Bufalo; Malcolm K Brenner
Journal:  Mol Ther       Date:  2015-05-29       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.